Aliases & Classifications for Tooth Disease

MalaCards integrated aliases for Tooth Disease:

Name: Tooth Disease 12 15 17
Tooth Diseases 43 71
Tooth Disorders 42

Classifications:



External Ids:

Disease Ontology 12 DOID:1091
MeSH 43 D014076
SNOMED-CT 67 72722003
UMLS 71 C0040435

Summaries for Tooth Disease

MedlinePlus : 42 What are teeth? Your teeth are made of a hard, bonelike material. There are four parts: Enamel, your tooth's hard surface Dentin, the hard yellow part under the enamel Cementum, the hard tissue that covers the root and keeps your teeth in place Pulp, the soft connective tissue in the center of your tooth. It contains nerves and blood vessels. You need your teeth for many activities that you may take for granted. These include eating, speaking and even smiling. What are tooth disorders? There are many different problems that can affect your teeth, including Tooth decay - damage to a tooth's surface, which can lead to cavities Abscess - a pocket of pus, caused by a tooth infection Impacted tooth - a tooth did not erupt (break through the gum) when it should have. It is usually wisdom teeth that are impacted, but it can sometimes happen to other teeth. Misaligned teeth (malocclusion) Tooth injuries such as broken or chipped teeth What causes tooth disorders? The causes of tooth disorders varies, depending on the problem. Sometimes the cause is not taking good care of your teeth. In other cases, you may have been born with the problem or the cause is an accident. What are the symptoms of tooth disorders? The symptoms can vary, depending on the problem. Some of the more common symptoms include Abnormal color or shape of the tooth Tooth pain Worn-down teeth How are tooth disorders diagnosed? Your dentist will ask about your symptoms, look at your teeth, and probe them with dental instruments. In some cases, you may need dental x-rays. What are the treatments for tooth disorders? The treatment will depend on the problem. Some common treatments are Fillings for cavities Root canals for cavities or infections that affect the pulp (inside of the tooth) Extractions (pulling teeth) for teeth that are impacted and causing problems or are too damaged to be fixed. You may also have a tooth or teeth pulled because of overcrowding in your mouth. Can tooth disorders be prevented? The main thing that you can do to prevent tooth disorders is to take good care of your teeth: Brush your teeth twice a day with a fluoride toothpaste Clean between your teeth every day with floss or another type of between-the-teeth cleaner Limit sugary snacks and drinks Don't smoke or chew tobacco See your dentist or oral health professional regularly

MalaCards based summary : Tooth Disease, also known as tooth diseases, is related to charcot-marie-tooth disease, axonal, type 2b1 and charcot-marie-tooth disease, axonal, type 2n, and has symptoms including halitosis, snoring and toothache. An important gene associated with Tooth Disease is MFN2 (Mitofusin 2), and among its related pathways/superpathways is Neural Crest Differentiation. The drugs Ketamine and Folic acid have been mentioned in the context of this disorder. Affiliated tissues include bone, testes and liver, and related phenotypes are Decreased viability and Decreased viability

Related Diseases for Tooth Disease

Diseases related to Tooth Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 524)
# Related Disease Score Top Affiliating Genes
1 charcot-marie-tooth disease, axonal, type 2b1 35.1 MFN2 LRSAM1 LMNA GDAP1
2 charcot-marie-tooth disease, axonal, type 2n 35.0 MFN2 KIF1B GDAP1
3 charcot-marie-tooth disease, axonal, type 2q 35.0 MPZ GJB1 EGR2
4 charcot-marie-tooth disease, axonal, type 2p 35.0 LRSAM1 LITAF GDAP1
5 charcot-marie-tooth disease, axonal, type 2a1 35.0 MPZ MFN2 LRSAM1 KIF1B GDAP1
6 charcot-marie-tooth disease, dominant intermediate a 34.9 MPZ GJB1 GDAP1
7 charcot-marie-tooth disease, dominant intermediate d 34.9 MPZ KIF1B
8 charcot-marie-tooth disease, type 4k 34.9 SH3TC2 LITAF
9 charcot-marie-tooth disease, dominant intermediate e 34.9 SH3TC2 SBF2 MTMR2 MPZ GDAP1
10 charcot-marie-tooth disease, recessive intermediate a 34.9 MFN2 GDAP1
11 charcot-marie-tooth disease, type 4b3 34.9 SH3TC2 SBF2 MTMR2 GDAP1
12 charcot-marie-tooth disease, axonal, type 2h 34.9 LRSAM1 GDAP1
13 charcot-marie-tooth disease, dominant intermediate b 34.9 SH3TC2 SBF2 MTMR2 MPZ LITAF GJB1
14 charcot-marie-tooth disease, axonal, type 2cc 34.9 NEFL MPZ MFN2 GJB1
15 charcot-marie-tooth disease, axonal, type 2b2 34.9 NEFL MPZ MFN2 MED25 LRSAM1 KIF1B
16 charcot-marie-tooth disease, axonal, type 2d 34.9 NEFL MPZ MFN2 KIF1B HSPB8 GJB1
17 charcot-marie-tooth disease, axonal, type 2r 34.8 LRSAM1 GDAP1
18 charcot-marie-tooth disease, type 4j 34.8 SH3TC2 SBF2 MTMR2 LITAF GDAP1 FIG4
19 charcot-marie-tooth disease, type 4b1 34.8 SH3TC2 SBF2 MTMR2 MPZ LITAF GDAP1
20 charcot-marie-tooth disease x-linked recessive 4 34.8 MPZ GJB1
21 charcot-marie-tooth disease, type 4h 34.8 SH3TC2 SBF2 NDRG1 MTMR2 MPZ GDAP1
22 charcot-marie-tooth disease, type 4a 34.8 SH3TC2 SBF2 MTMR2 MPZ MFN2 KIF1B
23 charcot-marie-tooth disease, axonal, type 2j 34.7 SH3TC2 SBF2 NEFL MTMR2 MPZ MFN2
24 charcot-marie-tooth disease, axonal, type 2l 34.7 NEFL MPZ MFN2 KIF1B HSPB8 HSPB1
25 charcot-marie-tooth disease, demyelinating, type 1d 34.7 PMP22 MTMR2 MPZ LITAF KIF1B GJB1
26 charcot-marie-tooth disease type 2a 34.7 MFN2 KIF1B
27 charcot-marie-tooth disease, type 4b2 34.7 SH3TC2 SBF2 MTMR2 MPZ LITAF GJB1
28 charcot-marie-tooth disease, x-linked recessive, 2 34.7 MPZ LITAF GJB1 EGR2
29 charcot-marie-tooth disease, axonal, type 2b 34.7 SH3TC2 SBF2 NEFL MTMR2 MPZ MFN2
30 charcot-marie-tooth disease, demyelinating, type 1f 34.7 SH3TC2 SBF2 NEFL MTMR2 MPZ LRSAM1
31 charcot-marie-tooth disease, axonal, type 2f 34.6 NEFL MTMR2 MPZ MFN2 KIF1B HSPB8
32 charcot-marie-tooth disease, demyelinating, type 1b 34.6 SH3TC2 SBF2 PMP22 MTMR2 MPZ MFN2
33 charcot-marie-tooth disease, dominant intermediate c 34.6 MPZ GDAP1
34 charcot-marie-tooth disease, x-linked dominant, 1 34.6 SH3TC2 PMP22 MTMR2 MPZ MFN2 LITAF
35 charcot-marie-tooth disease, type 4d 34.6 SH3TC2 SBF2 NDRG1 MTMR2 MPZ LITAF
36 charcot-marie-tooth disease, demyelinating, type 4f 34.6 SH3TC2 SBF2 MTMR2 MPZ LITAF GJB1
37 charcot-marie-tooth disease, demyelinating, type 1a 34.6 SH3TC2 SBF2 PMP22 NEFL MTMR2 MPZ
38 charcot-marie-tooth disease type 2a2a 34.6 SH3TC2 NEFL MPZ MFN2 LITAF KIF1B
39 charcot-marie-tooth disease, type 4c 34.6 SH3TC2 SBF2 MTMR2 MPZ MFN2 LITAF
40 charcot-marie-tooth disease, axonal, type 2i 34.5 SH3TC2 PMP22 MPZ MFN2 MED25 LITAF
41 charcot-marie-tooth disease type x 34.4 SH3TC2 PMP22 MTMR2 MPZ MFN2 KIF1B
42 charcot-marie-tooth disease, demyelinating, type 1c 34.3 SH3TC2 SBF2 PMP22 NEFL MTMR2 MPZ
43 charcot-marie-tooth disease intermediate type 34.3 SH3TC2 SBF2 MTMR2 MPZ MFN2 LRSAM1
44 neuropathy, hereditary motor and sensory, russe type 34.3 SH3TC2 NDRG1 GDAP1 EGR2
45 charcot-marie-tooth disease, axonal, type 2t 34.2 LRSAM1 GDAP1
46 hereditary motor and sensory neuropathy, type iic 34.1 SH3TC2 NEFL MPZ MFN2 LRSAM1 KIF1B
47 charcot-marie-tooth disease, axonal, type 2e 34.1 SH3TC2 SBF2 PMP22 NEFL NDRG1 MTMR2
48 charcot-marie-tooth disease and deafness 34.0 SH3TC2 SBF2 PMP22 NEFL NDRG1 MTMR2
49 charcot-marie-tooth disease 33.9 SH3TC2 SBF2 PMP22 NEFL NDRG1 MTMR2
50 roussy-levy hereditary areflexic dystasia 33.9 PMP22 MPZ

Graphical network of the top 20 diseases related to Tooth Disease:



Diseases related to Tooth Disease

Symptoms & Phenotypes for Tooth Disease

UMLS symptoms related to Tooth Disease:


halitosis, snoring, toothache, poor dentition

GenomeRNAi Phenotypes related to Tooth Disease according to GeneCards Suite gene sharing:

26 (show all 11)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 10.37 GJB1
2 Decreased viability GR00107-A-1 10.37 HSPB8
3 Decreased viability GR00221-A-1 10.37 HSPB8
4 Decreased viability GR00221-A-4 10.37 HSPB8
5 Decreased viability GR00240-S-1 10.37 LMNA
6 Decreased viability GR00301-A 10.37 HSPB8
7 Decreased viability GR00381-A-1 10.37 FGD4 FIG4 HSPB1 LRSAM1 MPZ SH3TC2
8 Decreased viability GR00381-A-3 10.37 MPZ
9 Decreased viability GR00402-S-2 10.37 EGR2 FGD4 FIG4 GDAP1 GJB1 HSPB1
10 no effect GR00402-S-1 9.62 EGR2 FGD4 FIG4 GDAP1 GJB1 HSPB1
11 Increased gamma-H2AX phosphorylation GR00053-A 9.56 EGR2 GJB1 HSPB1 LMNA MPZ NDRG1

MGI Mouse Phenotypes related to Tooth Disease:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.36 EGR2 FGD4 FIG4 GDAP1 GJB1 KIF1B
2 growth/size/body region MP:0005378 10.18 EGR2 FGD4 FIG4 GJB1 HSPB1 KIF1B
3 homeostasis/metabolism MP:0005376 10.18 EGR2 GDAP1 GJB1 HSPB1 HSPB8 KIF1B
4 mortality/aging MP:0010768 10.07 EGR2 FIG4 GJB1 HSPB8 KIF1B LMNA
5 limbs/digits/tail MP:0005371 9.92 EGR2 FIG4 GDAP1 KIF1B LMNA MED25
6 nervous system MP:0003631 9.89 EGR2 FGD4 FIG4 GDAP1 GJB1 KIF1B
7 muscle MP:0005369 9.76 FIG4 HSPB8 KIF1B LMNA MFN2 NDRG1
8 skeleton MP:0005390 9.28 EGR2 FIG4 KIF1B LMNA MED25 MFN2

Drugs & Therapeutics for Tooth Disease

Drugs for Tooth Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 96)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ketamine Approved, Vet_approved Phase 4 6740-88-1 3821
2
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
3 Trace Elements Phase 4
4 Vitamins Phase 4
5 Nutrients Phase 4
6 Micronutrients Phase 4
7 Antioxidants Phase 4
8 Protective Agents Phase 4
9 Analgesics Phase 4
10 Anesthetics, Dissociative Phase 4
11 Anesthetics, General Phase 4
12 Anesthetics, Intravenous Phase 4
13 Excitatory Amino Acid Antagonists Phase 4
14 Excitatory Amino Acids Phase 4
15 Alpha-lipoic Acid Phase 4
16 Vitamin B Complex Phase 4
17 Vitamin B9 Phase 4
18 Folate Phase 4
19 Thioctic Acid Phase 4
20
Ibuprofen Approved Phase 3 15687-27-1 3672
21
Caffeine Approved Phase 3 58-08-2 2519
22
Acetylcarnitine Approved, Investigational Phase 2, Phase 3 3040-38-8 7045767
23
Baclofen Approved Phase 3 1134-47-0 2284
24
Sorbitol Approved Phase 3 50-70-4 5780
25
Naltrexone Approved, Investigational, Vet_approved Phase 3 16590-41-3 5360515
26
Vitamin C Approved, Nutraceutical Phase 2, Phase 3 50-81-7 5785 54670067
27 Central Nervous System Stimulants Phase 3
28 Cyclooxygenase Inhibitors Phase 3
29 Anti-Inflammatory Agents, Non-Steroidal Phase 3
30 Analgesics, Non-Narcotic Phase 3
31 Phosphodiesterase Inhibitors Phase 3
32 Antirheumatic Agents Phase 3
33 carnitine Phase 2, Phase 3
34 Nootropic Agents Phase 2, Phase 3
35 Pharmaceutical Solutions Phase 3
36 Hematinics Phase 2, Phase 3
37 Epoetin alfa Phase 2, Phase 3 113427-24-0
38 Neuroprotective Agents Phase 2, Phase 3
39
Mexiletine Approved, Investigational Phase 2 31828-71-4 4178
40
Coenzyme Q10 Approved, Investigational, Nutraceutical Phase 1, Phase 2 303-98-0 5281915
41
Calcium Approved, Nutraceutical Phase 2 7440-70-2 271
42 Ubiquinone Phase 1, Phase 2
43 Calcium, Dietary Phase 2
44 4-des-dimethylaminotetracycline Phase 1, Phase 2
45
protease inhibitors Phase 1, Phase 2
46 HIV Protease Inhibitors Phase 1, Phase 2
47 Matrix Metalloproteinase Inhibitors Phase 1, Phase 2
48 Ulipristal acetate Phase 2 126784-99-4
49 Contraceptive Agents Phase 2
50
Ethanol Approved 64-17-5 702

Interventional clinical trials:

(show top 50) (show all 105)
# Name Status NCT ID Phase Drugs
1 Success Rate Evaluation of Miniature Pulpotomy With MTA in Primary Molars Unknown status NCT02286648 Phase 4 Formocresol;Mineral Trioxide Aggregate
2 Effect of Racemic Ketamine on Pain in Females and Males After Surgical Removal of Third Molars Completed NCT00232492 Phase 4 Placebo males;Ketamine 0,1 mg/kg males;Ketamine 0,3 mg/kg males;Ketamine 0,5 mg/kg males;Placebo females;Ketamine 0,1 mg/kg females;Ketamine 0,3 mg/kg females;Ketamine 0,5 mg/kg females
3 The Association of Alpha Lipoic Acid to the Median Nerve Decompression in the Carpal Tunnel Syndrome: a Randomized Controlled Trial. Completed NCT01895621 Phase 4
4 Lidocaine and Triamcinolone vs Saline Trigger Point Injection for Treatment of Chronic Abdominal Wall Pain Withdrawn NCT02748395 Phase 4 Triamcinolone;Lidocaine
5 A Multicenter Study to Evaluate the Effects on Charcot−Marie−Tooth Neuropathy Type 1A of a Composite Treadmill, Stretching and Proprioceptive Exercise (TreSPE) Rehabilitation Program. Unknown status NCT01289704 Phase 2, Phase 3
6 International, Multi-center, Randomized, Double-blind, Placebo-controlled Phase III Study Assessing in Parallel Groups the Efficacy and Safety of 2 Doses of PXT3003 in Patients With Charcot-Marie-Tooth Disease Type 1A Treated 15 Months Completed NCT02579759 Phase 3 PXT3003 dose 1;PXT3003 dose 2;placebo
7 A Randomized, Placebo-controlled, Double Masked 120 Subject "Futility Design" Clinical Trial of Ascorbic Acid Treatment of Charcot Marie Tooth Disease Type 1A. Completed NCT00484510 Phase 2, Phase 3 Ascorbic acid (Vitamin C);placebo
8 A Single-centre, Double-blind, Randomised, Two-stage, Parallel-group Study to Assess the Efficacy and Safety of the Fixed Dose Combination of Ibuprofen 400 mg and Caffeine 100 mg Versus Ibuprofen 400 mg, Caffeine 100 mg and Placebo in Patients With Postoperative Dental Pain Completed NCT01929031 Phase 3 ibuprofen + caffeine;ibuprofen;ibuprofen;caffeine;ibuprofen + caffeine;placebo;placebo;caffeine;ibuprofen;ibuprofen + caffeine
9 Acetyl-l-carnitine to Enhance Nerve Regeneration in Carpal Tunnel Syndrome; a Randomized Control Trial. Completed NCT02141035 Phase 2, Phase 3 Acetyl-l-carnitine;placebo
10 Clinical Evaluation of Cemented and Angulated Screw-retained Crowns Following Immediate Implant Placement: a Randomized Controlled Clinical Trials Recruiting NCT04160247 Phase 3
11 International, Multi-center, Open Label, 9-month Follow-up Extension Study Assessing the Long-term Safety and Tolerability of PXT3003 in Patients With Charcot-Marie-Tooth Disease Type 1A Active, not recruiting NCT03023540 Phase 3 PXT3003
12 Recombinant Human Erythropoietin (r-HuEPO) in the Prevention of Neurologic Sequelae From Malignant Spinal Cord Compression: a Multi-Center, Placebo-Controlled, Phase 2 Randomized Study Terminated NCT00220675 Phase 2, Phase 3 Erythropoietin infusion
13 SERENDEM : MD1003 in Patients Suffering From Demyelinating Neuropathies, an Open Label Pilot Study Unknown status NCT02967679 Phase 1, Phase 2 MD1003
14 A Phase II, Randomized, Placebo-controlled Trial of the Safety, Efficacy, Pharmacodynamics and Pharmacokinetics of PXT3003 in Patients With Charcot-Marie-Tooth Disease Type 1A. Completed NCT01401257 Phase 2 PXT3003 Low dose;PXT3003 Intermediate Dose;PXT3003 High Dose
15 Mexiletine for Muscle Cramps in Charcot Marie Tooth Disease Completed NCT02561702 Phase 2 Mexiletine
16 Effects of Coenzyme Q10 (CoQ10) on Subjects With Charcot-Marie-Tooth Disease (CMT):A Double Blind, Randomized, Controlled Trial With an Open Label Follow-up Study Completed NCT00541164 Phase 1, Phase 2 Coenzyme Q10
17 Phase 2 Study of Ascorbic Acid Treatment in Charcot-Marie-Tooth Type 1A Completed NCT00271635 Phase 2 Placebo;ascorbic acid
18 Neuropathy Along the Median Nerve: Etiology of Symptoms Associated With the Carpal Tunnel Syndrome, a Preliminary Study Completed NCT00634738 Phase 1, Phase 2
19 The Influence of Pronator Teres Release in the Treatment of Median Nerve Compression Neuropathy: A Randomized Prospective Study Recruiting NCT01562860 Phase 2
20 A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of ACE-083 in Patients With Charcot-Marie-Tooth Disease Types 1 and X Active, not recruiting NCT03124459 Phase 2 ACE-083;Placebo
21 A Randomized Controlled Clinical Trial of Regenerative Protocols to Treat Immature Necrotic Teeth Active, not recruiting NCT01827098 Phase 2
22 An Open-Label Extension Study to Evaluate the Long-Term Effects of ACE-083 in Patients With Facioscapulohumeral Muscular Dystrophy (FSHD) Previously Enrolled in Study A083-02 and in Patients With Charcot-Marie Tooth (CMT) Disease Types 1 and X Previously Enrolled in Study A083-03 Enrolling by invitation NCT03943290 Phase 2 ACE-083
23 Phase I/IIa Trial Evaluating scAAV1.tMCK.NTF3 for Treatment of Charcot-Marie-Tooth Neuropathy Type 1A (CMT1A) Not yet recruiting NCT03520751 Phase 1, Phase 2 scAAV1.tMCK.NTF3
24 A Randomized, Double-Blind, Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of FLX-787-ODT for Treatment of Muscle Cramps in Adult Subjects With Charcot-Marie-Tooth Disease Terminated NCT03254199 Phase 2 FLX-787-ODT (orally disintegrating tablet);Placebo ODT
25 LONG-TERM EFFECTS TOLERANCE AND THE Ulipristal Acetate IN DISEASE Charcot-MARIE-TOOTH TYPE OF 1A Terminated NCT02600286 Phase 2 EllaOne;EllaOne placebo
26 Tools for Therapeutic Evaluation in Charcot-Marie-Tooth Disease Type 1A: Outcome Measures and Biomarkers Unknown status NCT02596191
27 Development of the Charcot-Marie-Tooth Disease Infant Scale (CMTInfS) for Infants With CMT Unknown status NCT02979145
28 Evaluation of the Analgesic Efficiency of the Transcutaneous Neurostimulation in the Charcot Syndrome Marie Tooth on the Pains of Lower Limbs Unknown status NCT01918826
29 Clinical Trial of Safety and Efficacy of the Medical Item Collagen Plates With Hydroxyapol Inducing Angiogenesis, "Nukleostim", for Bone Tissue Regeneration Unknown status NCT02293031
30 Regenerative Endodontic Procedure of Immature Permanent Teeth With Apical Periodontitis Using Platelet-rich Fibrin : A Pilot Randomized Controlled Trial Unknown status NCT02801552
31 Linkage and Identification of (a) Candidate Gene(s) for Tooth Disorders Unknown status NCT00026026
32 Muscle Oxygenation Modification During Effort in 4 Groups of Neuromuscular Diseases Compared to Healthy Controls, and Mitochondrial Function and Phenotype Assessment Unknown status NCT02789059
33 Prospective Randomized Controlled Trial Comparing Extramembranous and Interosseous Technique of Tibialis Posterior Tendon Transfer. Unknown status NCT01751503
34 Clinical and Genetic Features of Familial Neuropathy Completed NCT00149045
35 Development and Validation of a Disability Severity Index for Charcot Marie Tooth Disease Completed NCT01455623
36 Correlation Between Clinical and Electrophysiological Phenotypes in a Population of Patients With Neuropathy Charcot-Marie-Tooth Disease Type 1A Completed NCT01750710
37 Survey of Current Management of Orthopaedic Complications in Charcot Marie Tooth Disease Patients Completed NCT02001038
38 Disability Severity Scale (DSI) and Hereditary Motor and Sensory Neuropathy Overall Disability Scale (HMSN-R-ODS) Completed NCT02194010
39 A Prospective Randomized-controlled Evaluation of Nanotite and Osseotite Surfaced Implant Performance in Graduate Student Programs Completed NCT00726063
40 A Prospective, Multicenter, Randomized Multicenter Study of Short Implants Used to Obviate the Need for Sinus Augmentation: an Assessment of Clinical Outcomes and Resource Allocation. Completed NCT00725049
41 An Analysis of the Symptomatic Domains Most Relevant to Charcot Marie Tooth Neuropathy (CMT) Patients Completed NCT02429947
42 MRI of the Brachial Plexus and Chronic Inflammatory Demyelinating Polyradiculoneuropathy: Assessment of DTI-derived Measurements at 3.0-T Completed NCT03460951
43 Performance and Tolerability of a New Medical Device Coating Gel for the Temporary Relief of Teething Symptoms: a Randomized, Open Label, Parallel-group, Multicentre Study Completed NCT03423784
44 Noninvasive Assessment of Neuromuscular Disease Using Electrical Impedance Completed NCT02011204
45 A Prospective, Randomized-Controlled, Multicenter Study of NanoTite Implants Placed Into Fresh Sinus Lift Augmentation Sites Completed NCT00713206
46 Patient Reported Outcomes Measures (PROM) in Carpal Tunnel Therapies in Patients With Inherited Neuropathies Completed NCT02788734
47 A Prospective, Observational Study of Immediate Loading Cases Using Osseotite Certain Tapered Implants Completed NCT01529762
48 BALTiC Study: A Feasibility Analysis of Home Based BALance Training in People With Charcot-Marie-Tooth Disease Completed NCT02982343
49 A Prospective Randomized-controlled Study of the Effect of Surface Topographies on Implant Integration Rates and Clinical Success Completed NCT01529801
50 A Prospective Randomized-controlled Evaluation of the Osseotite Certain Tapered Prevail Implant for the Preservation of Crestal Bone Completed NCT01529775

Search NIH Clinical Center for Tooth Disease

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Camphor
CAMPHOR CRYSTALS
CAMPHOR GUM
CAMPHOR,MONOBROMATED

Cochrane evidence based reviews: tooth diseases

Genetic Tests for Tooth Disease

Anatomical Context for Tooth Disease

MalaCards organs/tissues related to Tooth Disease:

40
Bone, Testes, Liver, Lung, Brain, Spinal Cord, Skin

Publications for Tooth Disease

Articles related to Tooth Disease:

(show top 50) (show all 3032)
# Title Authors PMID Year
1
Retention of pit and fissure sealant versus flowable composite: An in vivo one-year comparative evaluation. 42
31710012 2019
2
Comparative evaluation of antimicrobial effectiveness of probiotic milk and fluoride mouthrinse on salivary Streptococcus mutans counts and plaque scores in children - An in vivo experimental study. 42
31710013 2019
3
Randomized clinical trial of four adhesion strategies: A 42 month study. 42
31745040 2019
4
Unfolded protein response in myelin disorders. 61
31638085 2020
5
Identification of novel pathogenic copy number variations in Charcot-Marie-Tooth disease. 61
31852984 2020
6
Eye movements in demyelinating, autoimmune and metabolic disorders. 61
31770124 2020
7
Gene therapy approaches targeting Schwann cells for demyelinating neuropathies. 61
31790684 2020
8
Ring-shaped subpulmonic infundibular membrane diagnosed in an adult affected by type II Charcot-Marie-Tooth disease. 61
32026849 2020
9
Mitochondrial impairment activates the Wallerian pathway through depletion of NMNAT2 leading to SARM1-dependent axon degeneration. 61
31740269 2020
10
Neuromuscular Mimics of Entrapment Neuropathies of Upper Extremities. 61
32020820 2020
11
Are we prepared for clinical trials in Charcot-Marie-Tooth disease? 61
31899213 2020
12
Clinical and Genetic Features in a Series of Eight Unrelated Patients with Neuropathy Due to Glycyl-tRNA Synthetase (GARS) Variants. 61
31985473 2020
13
Oxidative stress contributes differentially to the pathophysiology of Charcot-Marie-Tooth disease type 2K. 61
31655048 2020
14
Expansion of the phenotypic spectrum of X-linked Charcot-Marie-Tooth (CMT) disease. 61
31987637 2020
15
Old but Gold: Tracking the New Guise of Histone Deacetylase 6 (HDAC6) Enzyme as a Biomarker and Therapeutic Target in Rare Diseases. 61
31415174 2020
16
7T MR neurography-ultrasound fusion for peripheral nerve imaging. 61
31899543 2020
17
Targeted next-generation sequencing panels in the diagnosis of Charcot-Marie-Tooth disease. 61
31827005 2020
18
Neurological safety of oxaliplatin in patients with uncommon variants in Charcot-Marie-tooth disease genes. 61
32018185 2020
19
Extensor Tendon Transfers for Treatment of Foot Drop in Charcot-Marie-Tooth Disease: A Biomechanical Evaluation. 61
31941350 2020
20
Evidence for Cognitive Deficits in X-Linked Charcot-Marie-Tooth Disease. 61
31948496 2020
21
Gene therapies for axonal neuropathies: Available strategies, successes to date, and what to target next. 61
32001243 2020
22
HDAC6 inhibitors: translating genetic and molecular insights into a therapy for axonal CMT. 61
32006555 2020
23
Identification of CR43467 encoding a long non-coding RNA as a novel genetic interactant with dFIG4, a CMT-causing gene. 61
31704059 2020
24
A novel GJB1 mutation associated with X-linked Charcot-Marie-Tooth disease in a large Chinese family pedigree. 61
31943912 2020
25
Prevalence, Mortality, and Cause of Death in Charcot-Marie-Tooth Disease in Korea: A Nationwide, Population-Based Study. 61
31995800 2020
26
A case report of trisomy 17 mosaicism: PMP22 gene duplication as a result of trisomy 17 associated with Charcot-Marie-Tooth disease. 61
31688096 2020
27
Gene therapy to promote regeneration in Charcot-Marie-Tooth disease. 61
31669284 2020
28
Targeted PMP22 TATA-box editing by CRISPR/Cas9 reduces demyelinating neuropathy of Charcot-Marie-Tooth disease type 1A in mice. 61
31713617 2020
29
Targeting the programmed axon degeneration pathway as a potential therapeutic for Charcot-Marie-Tooth disease. 61
31689415 2020
30
Charcot-Marie-Tooth disease: experience from a large Italian tertiary neuromuscular center. 61
31902012 2020
31
An update on clinical, pathological, diagnostic, and therapeutic perspectives of childhood leukodystrophies. 61
31829048 2020
32
Whole exome sequencing reveals a broader variant spectrum of Charcot-Marie-Tooth disease type 2. 61
31832804 2019
33
BAG3 p.Pro209Ser mutation identified in a Chinese family with Charcot-Marie-Tooth disease. 61
31853710 2019
34
ATP1A1 mutations cause intermediate Charcot-Marie-Tooth disease. 61
31373411 2019
35
Charcot-Marie-Tooth Disease Type 4J and Multiple Sclerosis. 61
31743256 2019
36
Plasticity in salt bridge allows fusion-competent ubiquitylation of mitofusins and Cdc48 recognition. 61
31740565 2019
37
S1P/S1P Receptor Signaling in Neuromuscolar Disorders. 61
31861214 2019
38
Reduction of Rpd3 suppresses defects in locomotive ability and neuronal morphology induced by the knockdown of Drosophila SLC25A46 via an epigenetic pathway. 61
31614134 2019
39
Recurrent episodes of reversible posterior leukoencephalopathy in three Chinese families with GJB1 mutations in X-linked Charcot-Marie-tooth type 1 disease: cases report. 61
31842800 2019
40
Severe Consequences of SAC3/FIG4 Phosphatase Deficiency to Phosphoinositides in Patients with Charcot-Marie-Tooth Disease Type-4J. 61
31313076 2019
41
Allele-specific RNA interference prevents neuropathy in Charcot-Marie-Tooth disease type 2D mouse models. 61
31557132 2019
42
Long term results of the revisited Meary closing wedge tarsectomy for the treatment of the fixed cavo-varus foot in adolescent with Charcot-Marie-Tooth disease. 61
30482439 2019
43
Charcot-Marie-Tooth disease with a mutation in FBLN5 accompanying with the small vasculitis and widespread onion-bulb formations. 61
31945625 2019
44
Downregulation of the human peripheral myelin protein 22 gene by miR-29a in cellular models of Charcot-Marie-Tooth disease. 61
31455873 2019
45
Insights into wild-type dynamin 2 and the consequences of DNM2 mutations from transgenic zebrafish. 61
31691805 2019
46
Identification of TYW3/CRYZ and FGD4 as susceptibility genes for amyotrophic lateral sclerosis. 61
31872054 2019
47
Nerve size correlates with clinical severity in Charcot-Marie-Tooth disease 1A. 61
31469427 2019
48
Foot Function Index: A Promising Questionnaire for Individuals With Charcot-Marie-Tooth Disease Type 1A. 61
31255638 2019
49
Implication of the SH3TC2 gene in Charcot-Marie-Tooth disease associated with deafness and/or scoliosis: Illustration with four new pathogenic variants. 61
31634715 2019
50
Genetic spectrum and clinical profiles in a southeast Chinese cohort of Charcot-Marie-Tooth disease. 61
31372974 2019

Variations for Tooth Disease

Expression for Tooth Disease

Search GEO for disease gene expression data for Tooth Disease.

Pathways for Tooth Disease

Pathways related to Tooth Disease according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 10.81 PMP22 MPZ GJB1

GO Terms for Tooth Disease

Cellular components related to Tooth Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytosol GO:0005829 9.93 SBF2 NEFL NDRG1 MTMR2 MFN2 LRSAM1
2 vacuolar membrane GO:0005774 9.26 SBF2 MTMR2
3 endosome membrane GO:0010008 9.26 SBF2 MTMR2 LITAF FIG4
4 axon cytoplasm GO:1904115 8.8 NEFL KIF1B HSPB1

Biological processes related to Tooth Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 phosphatidylinositol metabolic process GO:0046488 9.4 MTMR2 FIG4
2 mitochondrial fusion GO:0008053 9.37 MFN2 GDAP1
3 negative regulation of endocytosis GO:0045806 9.32 MTMR2 LRSAM1
4 negative regulation of myelination GO:0031642 9.26 MTMR2 FIG4
5 myelination GO:0042552 9.26 SBF2 PMP22 MPZ EGR2
6 peripheral nervous system myelin maintenance GO:0032287 9.16 SH3TC2 NDRG1
7 myelin assembly GO:0032288 8.8 PMP22 MTMR2 FIG4

Molecular functions related to Tooth Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 phosphatidylinositol-3-phosphatase activity GO:0004438 8.62 MTMR2 FIG4

Sources for Tooth Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....